Targeted delivery of bone growth factors
CA 2102808 A1 · Owner: Celtrix Pharmaceuticals, Inc. · Inventors: Bentz, Hanne; Rosen, David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions for using conjugates of bone growth factors and targeting molecules in bone repair and augmentation are provided. The bone growth factor and targeting molecule are chemically conjugated to a crosslinker. The crosslinker is preferably a synthetic hydrophilic polymer. The bone growth factor is preferably TGF-.beta. activin, or bone morphogenic protein (BMP). Targeting molecules preferably have an affinity for bone such as, tetracycline, calcein, bisphosphonate polyaspartic acid, polyglutamic, acid, aminophosphosugars or estrogen.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 7, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 7, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 7, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.